v3.26.1
LICENSE, COLLABORATION AND OTHER REVENUE - MTPC Collaboration Agreement - Narrative (Details)
$ in Thousands
3 Months Ended
Dec. 11, 2015
USD ($)
performance_obligation
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Total revenues   $ 53,544 $ 57,336  
Accounts receivable, net   62,536   $ 47,031
Payables   8,386   $ 21,185
Revenue recognized   0 0  
Tanabe Pharma Corporation        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Total revenues $ 9,000      
Tanabe Pharma Corporation | Royalty payments        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Total revenues   300 400  
Tanabe Pharma Corporation | Regulatory Milestone Payments        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Milestone revenue $ 25,000 25,000    
Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of performance obligations | performance_obligation 2      
Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront cash payment received $ 20,000      
Cost of research services 20,500      
Milestone revenue $ 10,000      
Deferred revenue   0    
Accounts receivable, net   0    
Payables   0    
Contract asset   300    
Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Deferred revenue   0    
Accounts receivable, net   0    
Payables   0    
Revenue recognized   $ 0 $ 0